The ASCO abstract acceptance and preclinical synergy data are incremental positive signals for the platform, but the company remains pre-revenue with no near-term catalyst until the Phase 1 trial start (mid-2027). Monitor for further preclinical data releases and any financing updates given the $18M market cap.
Price Chart
Executive Summary
Akari Therapeutics announced CEO participation in a Virtual Investor interview discussing its first ASCO abstract acceptance, highlighting preclinical data showing synergy between its PH1 spliceosome-modulating ADC platform and a KRAS inhibitor in pancreatic cancer models. The company targets a Phase 1 first-in-human trial start by mid-2027, but no new financial data or regulatory milestones were disclosed.
Key Facts
- First ASCO abstract acceptance for Akari, presenting preclinical data on AKTX-101 and PH1 payload platform.
- Preclinical data demonstrated combination synergy between Akari's ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models.
- Company targets initiation of Phase 1 first-in-human clinical trial by mid-2027.
- No new financial data, revenue, or earnings disclosed in the press release.
- AKTX-101 targets Trop2 receptor; AKTX-102 targets CEACAM5, both using PH1 spliceosome-modulating payload.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage biotech with $18M market cap.
Risk Factors
- No revenue or near-term commercial product; requires additional capital to fund operations and clinical trials.
- Phase 1 trial start is targeted for mid-2027, with significant execution risk and potential delays.
- Preclinical data may not translate to clinical efficacy; KRAS-driven cancers remain difficult to treat.
- Small market cap ($18M) implies high volatility and limited liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3302971 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.58 (−1.61%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.58 (+13.79%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.58 (+36.07%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.58 (−39.62%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.58 (+17.58%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.58 (−11.46%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.58 (−61.09%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.58 (+51.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers